Abpro Corporation
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Abpro Corporation is a biotechnology company specializing in the development of next-generation antibody therapeutics aimed at treating severe and life-threatening diseases. The company primarily focuses on immuno-oncology and ophthalmology through novel antibody constructs developed via its proprietary DiversImmune and MultiMab antibody discovery and engineering platforms. Its core products include antibody therapeutics such as ABP-102 and ABP-201, which feature a tetravalent bispecific antibody format designed to engage the immune system; ABP-102, notably, is a HER2 x CD3 T-cell engager targeting HER2-positive cancers including breast, gastric, and pancreatic cancers. Additionally, Abpro develops treatments for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and infectious diseases. Founded in 2007 and headquartered in Woburn, Massachusetts, Abpro operates globally with significant collaborations and business in both the U.S. and Asian markets. The company has a strategic partnership with Celltrion, a South Korean biopharmaceutical firm, for the worldwide development and commercialization of ABP-102. This collaboration includes Celltrion funding all developmental expenses for ABP-102, with clinical trials anticipated to begin in the first half of 2026 and Celltrion holding global commercialization rights. The partnership is structured with potential equity investments and milestone payments totaling up to $1.75 billion. Recent major company developments include a business combination with Atlantic Coastal Acquisition Corp. II, completed in late 2024, which raised approximately $10 million in gross proceeds through PIPE offerings and convertible notes. In 2025, Abpro executed a 1-for-30 reverse stock split to maintain Nasdaq compliance and reduce operating costs by an estimated 60%. Leadership changes occurred with the departure of former CEO Ian Chan, succeeded by Board Chairman Miles Suk, without altering the company's strategic direction. Additionally, Abpro presented preclinical data for ABP-102/CT-P72 at the AACR Annual Meeting 2025, underscoring its potential as a best-in-class therapy for HER2-positive cancers. Abpro targets patients with unmet medical needs across oncology and ophthalmology sectors, leveraging collaborations with global pharmaceutical and research institutions to advance its pipeline. The company’s business model integrates proprietary technology platforms with partnership-driven development and commercialization efforts, aiming to deliver advanced antibody therapies worldwide. This comprehensive focus on advanced antibody therapeutics, strategic global partnerships, recent capital market activities, and leadership evolution define Abpro Corporation’s current operational and strategic profile.
Short Interest in Abpro Holdings Inc. (NASDAQ:ABP) Increases By 271.4%
Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy?
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Abpro Holdings Inc. (NASDAQ:ABP) Sees Large Decrease in Short Interest
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Abpro Statement on the Departure of Former CEO Ian Chan
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing